These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

779 related articles for article (PubMed ID: 28170370)

  • 1. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
    Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples.
    Pepe F; De Luca C; Smeraglio R; Pisapia P; Sgariglia R; Nacchio M; Russo M; Serra N; Rocco D; Battiloro C; Ambrosio F; Gragnano G; Vigliar E; Bellevicine C; Troncone G; Malapelle U
    J Clin Pathol; 2019 Jan; 72(1):38-45. PubMed ID: 30279174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.
    Dowler Nygaard A; Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Oncol Rep; 2014 Feb; 31(2):969-74. PubMed ID: 24316734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.
    Li BT; Janku F; Jung B; Hou C; Madwani K; Alden R; Razavi P; Reis-Filho JS; Shen R; Isbell JM; Blocker AW; Eattock N; Gnerre S; Satya RV; Xu H; Zhao C; Hall MP; Hu Y; Sehnert AJ; Brown D; Ladanyi M; Rudin CM; Hunkapiller N; Feeney N; Mills GB; Paweletz CP; Janne PA; Solit DB; Riely GJ; Aravanis A; Oxnard GR
    Ann Oncol; 2019 Apr; 30(4):597-603. PubMed ID: 30891595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
    Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
    Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
    Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
    Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B
    Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
    Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ
    Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
    Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
    Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.
    Paweletz CP; Sacher AG; Raymond CK; Alden RS; O'Connell A; Mach SL; Kuang Y; Gandhi L; Kirschmeier P; English JM; Lim LP; Jänne PA; Oxnard GR
    Clin Cancer Res; 2016 Feb; 22(4):915-22. PubMed ID: 26459174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of KRAS, NRAS and BRAF hotspot mutations detection for patients with metastatic colorectal cancer using direct DNA pipetting in a fully-automated platform and Next-Generation Sequencing for laboratory workflow optimisation.
    Gilson P; Franczak C; Dubouis L; Husson M; Rouyer M; Demange J; Perceau M; Leroux A; Merlin JL; Harlé A
    PLoS One; 2019; 14(7):e0219204. PubMed ID: 31265477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
    Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
    J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid clinical mutational testing of
    Van Haele M; Vander Borght S; Ceulemans A; Wieërs M; Metsu S; Sagaert X; Weynand B
    J Clin Pathol; 2020 Jan; 73(1):35-41. PubMed ID: 31296605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer.
    Ohira T; Sakai K; Matsubayashi J; Kajiwara N; Kakihana M; Hagiwara M; Hibi M; Yoshida K; Maeda J; Ohtani K; Nagao T; Nishio K; Ikeda N
    Cancer Sci; 2016 Nov; 107(11):1660-1666. PubMed ID: 27575703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
    Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
    Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer.
    Palmero R; Taus A; Viteri S; Majem M; Carcereny E; Garde-Noguera J; Felip E; Nadal E; Malfettone A; Sampayo M; Riva F; Nagy RJ; Lanman RB; Faull I; Dix D; Karachaliou N; Rosell R
    JCO Precis Oncol; 2021 Nov; 5():93-102. PubMed ID: 34994593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.